X4 Pharmaceuticals to Present at the 20th Annual Needham Virtual Healthcare Conference

Rhea-AI Summary

X4 Pharmaceuticals (Nasdaq: XFOR) is set to present a corporate overview at the 20th Annual Needham Virtual Healthcare Conference on April 12, 2021, at 2:15 PM ET. The presentation will focus on their innovative therapies targeting the CXCR4 pathway, particularly the lead candidate, mavorixafor, a unique treatment aimed at rare diseases. A live webcast will be available on the company's website, with an archive accessible for 90 days following the event.

BOSTON, April 07, 2021 (GLOBE NEWSWIRE) -- X4 Pharmaceuticals, Inc. (Nasdaq: XFOR), a leader in the discovery and development of novel therapies targeting diseases resulting from dysfunction of the CXCR4 pathway, today announced that management will present a corporate overview at the 20^th Annual Needham Virtual Healthcare Conference on Monday, April 12, 2021.

Details are as follows:
Conference: 20^th Annual Needham Virtual Healthcare Conference
Date: Monday, April 12, 2021
Time: 2:15 PM ET
Presentation Webcast Link

A live webcast of the presentation from the Needham Virtual Healthcare Conference will be available on the investors section of the X4 Pharmaceuticals’ website at www.x4pharma.com.   After the live webcast, the event will remain archived on the X4 Pharmaceuticals’ website for approximately 90 days.

About X4 Pharmaceuticals
X4 Pharmaceuticals is a late-stage clinical biopharmaceutical company and a leader in the discovery and development of novel therapies for the treatment of diseases resulting from dysfunction of the CXCR4 pathway, with a focus on rare diseases and those with limited treatment options. The company’s lead candidate, mavorixafor, is a first-in-class, small molecule antagonist of chemokine receptor CXCR4 being developed as a once-daily oral therapy. X4 believes that inhibition of the CXCR4 receptor creates the potential for mavorixafor to provide therapeutic benefit across a wide variety of diseases, including primary immunodeficiencies and certain types of cancer. The efficacy and safety of mavorixafor, dosed once daily, is currently being evaluated in a global Phase 3 clinical trial in patients with WHIM syndrome, and in two Phase 1b clinical trials – in combination with ibrutinib in patients with Waldenström’s macroglobulinemia, and as monotherapy in patients with Severe Congenital Neutropenia. X4 is continuing to leverage its insights into CXCR4 biology at its corporate headquarters in Boston, Massachusetts and at its research facility in Vienna, Austria, and is discovering and developing additional product candidates. For more information, please visit www.x4pharma.com.

Investors and Media: 
Daniel Ferry
Managing Director
LifeSci Advisors
daniel@lifesciadvisors.com
(617) 430-7576

Mónica Rouco Molina
Senior Account Executive
LifeSci Communications
mroucomolina@lifescicomms.com 

FAQ

What is X4 Pharmaceuticals presenting at the 20th Annual Needham Virtual Healthcare Conference?

X4 Pharmaceuticals will present a corporate overview highlighting their therapies targeting the CXCR4 pathway.

When is X4 Pharmaceuticals' presentation at the Needham Virtual Healthcare Conference?

The presentation is scheduled for April 12, 2021, at 2:15 PM ET.

Where can I watch the X4 Pharmaceuticals presentation?

The presentation will be streamed live on X4 Pharmaceuticals' website, with an archived version available for 90 days.

What is mavorixafor being developed for by X4 Pharmaceuticals?

Mavorixafor is being developed as a treatment for rare diseases, including primary immunodeficiencies and certain cancers.

What stage is mavorixafor currently in clinical trials?

Mavorixafor is in a global Phase 3 clinical trial for WHIM syndrome and in Phase 1b trials for other conditions.